CARLSBAD, Calif.--(BUSINESS WIRE)--$LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, ...
Objectives In Breakfree-1 (NCT05869955), BMS-986353 (CD19 NEX-T®), a CD19-directed CAR T cell therapy, showed promising early safety and efficacy in severe, refractory SLE. We report updated data for ...
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 Provided by Business Wire Feb 26, 2026, 5:00:00 AM ...
WILMINGTON, Mass., February 25, 2026--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has signed definitive agreements to sell certain European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results